INTRODUCTION: Dysregulation of GABAergic inhibition and glutamatergic excitation has been implicated in exaggerated anxiety. Mouse pups emit distress-like ultrasonic vocalizations (USVs) when they are separated from their dam/siblings, and this behavior is reduced by benzodiazepines (BZs) which modulate GABAergic inhibition. The roles of glutamate receptors on USVs remain to be investigated. MATERIALS AND METHODS: We examined the roles of glutamate receptor subtypes on mouse pup USVs using N-methyl-D: -aspartate (NMDA) receptor antagonists with different affinities [dizocilpine (MK-801), memantine, and neramexane] and group II metabotropic glutamate receptor agonist (LY-379268) and antagonist (LY-341495). These effects were compared with classic BZs: flunitrazepam, bromazepam, and chlordiazepoxide. To assess the role of GABA(A) receptor subunits on USVs, drugs that have preferential actions at different GABA(A)-alpha subunits (L-838417 and QH-ii-066) were tested. Seven-day-old CFW mouse pups were separated from their dam and littermates and placed individually on a 19 degrees C test platform for 4 min. Grid crossings and body rolls were measured in addition to USVs. RESULTS: Dizocilpine dose-dependently reduced USVs, whereas memantine and neramexane showed biphasic effects and enhanced USVs at low to moderate doses. The NMDA receptor antagonists increased locomotion. LY-379268 reduced USVs but also suppressed locomotion. All BZs reduced USVs and increased motor incoordination. Neither L-838417 nor QH-ii-066 changed USVs, but both induced motor incoordination. CONCLUSION: Low-affinity NMDA receptor antagonists, but not the high-affinity antagonist, enhanced mouse pup distress calls, which may be reflective of an anxiety-like state. BZs reduced USVs but also induced motor incoordination, possibly mediated by the alpha5 subunit containing GABA(A) receptors.
INTRODUCTION: Dysregulation of GABAergic inhibition and glutamatergic excitation has been implicated in exaggerated anxiety. Mouse pups emit distress-like ultrasonic vocalizations (USVs) when they are separated from their dam/siblings, and this behavior is reduced by benzodiazepines (BZs) which modulate GABAergic inhibition. The roles of glutamate receptors on USVs remain to be investigated. MATERIALS AND METHODS: We examined the roles of glutamate receptor subtypes on mouse pup USVs using N-methyl-D: -aspartate (NMDA) receptor antagonists with different affinities [dizocilpine (MK-801), memantine, and neramexane] and group II metabotropic glutamate receptor agonist (LY-379268) and antagonist (LY-341495). These effects were compared with classic BZs: flunitrazepam, bromazepam, and chlordiazepoxide. To assess the role of GABA(A) receptor subunits on USVs, drugs that have preferential actions at different GABA(A)-alpha subunits (L-838417 and QH-ii-066) were tested. Seven-day-old CFW mouse pups were separated from their dam and littermates and placed individually on a 19 degrees C test platform for 4 min. Grid crossings and body rolls were measured in addition to USVs. RESULTS:Dizocilpine dose-dependently reduced USVs, whereas memantine and neramexane showed biphasic effects and enhanced USVs at low to moderate doses. The NMDA receptor antagonists increased locomotion. LY-379268 reduced USVs but also suppressed locomotion. All BZs reduced USVs and increased motor incoordination. Neither L-838417 nor QH-ii-066 changed USVs, but both induced motor incoordination. CONCLUSION: Low-affinity NMDA receptor antagonists, but not the high-affinity antagonist, enhanced mouse pup distress calls, which may be reflective of an anxiety-like state. BZs reduced USVs but also induced motor incoordination, possibly mediated by the alpha5 subunit containing GABA(A) receptors.
Authors: Paola V Plazas; Jessica Savino; Sebastian Kracun; María E Gomez-Casati; Eleonora Katz; Christopher G Parsons; Neil S Millar; Ana B Elgoyhen Journal: Eur J Pharmacol Date: 2007-03-24 Impact factor: 4.432
Authors: Rebecca Dias; Wayne F A Sheppard; Rosa L Fradley; Elizabeth M Garrett; Joanna L Stanley; Spencer J Tye; Simon Goodacre; Rachael J Lincoln; Susan M Cook; Rachel Conley; David Hallett; Alexander C Humphries; Sally A Thompson; Keith A Wafford; Leslie J Street; J Luis Castro; Paul J Whiting; Thomas W Rosahl; John R Atack; Ruth M McKernan; Gerard R Dawson; David S Reynolds Journal: J Neurosci Date: 2005-11-16 Impact factor: 6.167
Authors: Chad J Swanson; Mark Bures; Michael P Johnson; Anni-Maija Linden; James A Monn; Darryle D Schoepp Journal: Nat Rev Drug Discov Date: 2005-02 Impact factor: 84.694
Authors: James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson Journal: Proc Natl Acad Sci U S A Date: 2005-01-11 Impact factor: 11.205
Authors: Benjamin D Drever; William G L Anderson; Helena Johnson; Matthew O'Callaghan; Sangwon Seo; Deog-Young Choi; Gernot Riedel; Bettina Platt Journal: J Alzheimers Dis Date: 2007-12 Impact factor: 4.472
Authors: Faycal Guedj; Jeroen L A Pennings; Millie A Ferres; Leah C Graham; Heather C Wick; Klaus A Miczek; Donna K Slonim; Diana W Bianchi Journal: Am J Med Genet A Date: 2015-05-14 Impact factor: 2.802
Authors: Markus Wöhr; Jill L Silverman; Maria L Scattoni; Sarah M Turner; Mark J Harris; Roheeni Saxena; Jacqueline N Crawley Journal: Behav Brain Res Date: 2012-07-20 Impact factor: 3.332
Authors: Benjamin D Sachs; Ramona M Rodriguiz; Ha L Tran; Akshita Iyer; William C Wetsel; Marc G Caron Journal: Psychoneuroendocrinology Date: 2015-01-06 Impact factor: 4.905